Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Clinical trial NCT05209074 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05209074
Sponsor: Case Comprehensive Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Cancer

Start date: 2022-09-08
Primary completion: 2026-07-15
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.